Outcome Capital Recruits Peter F. Meyer to its Management Team

Outcome Capital has appointed Peter F. Meyer, Ph.D., as managing director in its Boston office. Dr. Meyer is tasked with expanding the firm’s medical device and life sciences services practices within Outcome’s strategy-driven platform, providing M&A, capital raising, and advisory services to clients.
 
An industry veteran with more than 25 years of strategic investment and commercial execution experience in medtech and life sciences, Dr. Meyer brings to his position a professional focus on leveraging best practices for strategy development, market entry, and growth acceleration. He has represented buy-side and sell-side interests across numerous clinical segments and business models, closing more than $3 billion in acquisition, partnership, and equity investments.
 
“We have an increasing number of mid- to growth-stage companies seeking sound strategies for mergers and acquisitions, private debt and equity placement, and other strategic and corporate finance advisory services,” Outcome Capital Managing Partner Dr. Oded Ben-Joseph said. “Unique among investment banking firms, Outcome’s strategic approach to value enhancement relies on significant corporate and operational experience. Peter brings deep domain expertise across multiple disciplines and will complement Outcome’s entrepreneurial culture.”
 
Before joining Outcome Capital, Dr. Meyer was vice president of Strategy and Corporate Development at Vicarious Surgical, an early-stage developer of soft-tissue surgical robotics. He previously worked as senior director of Business Development for Insulet Corporation, orchestrating investments in margin and portfolio expansion for the diabetes technology developer. In a series of increasingly senior roles within Medtronic and Covidien, Dr. Meyer supervised corporate transformational growth programs and implemented best practices for strategic business optimization.
 
Dr. Meyer earned a Ph.D. in biomedical engineering from Boston University, a bachelor of science degree in mechanical engineering from Columbia University, and a bachelor of science in math, physics, and chemistry from Providence College. He is a certified Design for Six Sigma Black Belt and holds more than 30 patents in medical technology.
 
“I’m thrilled to join Outcome Capital’s team; I look forward to leveraging Outcome’s strategy-led execution approach and my own experience as a strategic acquirer to help our clients find and prepare for an appropriate exit transaction,” Dr. Meyer stated.
 
Outcome Capital is a highly specialized life sciences and healthcare advisory and investment banking firm, providing companies with a value-added, market-aligned approach to mergers and acquisitions, partnering, and corporate finance. The firm leverages its “strategy-led execution” approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm employs multi-disciplinary industry experts who draw from their relationships and varied scientific, operational, strategic, and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, Ph.D./M.D.-level scientists and clinicians, and experienced commercialization experts, Outcome’s team helps propel innovation from bench to bedside.